Stories about Effector (biology)

Subscribe to Effector (biology)

02.11.2020 – 14:21

Technische Universität München
Immune response: memory T cells are formed earlier than previously thought

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22562 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36297/ NEWS RELEASE How the immune system remembers viruses Immune response: memory T cells are formed earlier than previously thought For a person to ...

more
14.09.2020 – 00:05

Merck KGaA
Merck Advances Oncology Portfolio and Pipeline with New and Long-term Data in Multiple Cancers at ESMO 2020

Darmstadt, Germany (ots/PRNewswire) - · New analyses from Phase III JAVELIN Bladder 100 study of BAVENCIO®* assess efficacy across subgroups, patient-reported outcomes and exploratory biomarkers in advanced urothelial cancer · Overall efficacy data, and analyses of brain metastases and HRQoL for tepotinib? from ...

more
14.05.2020 – 00:23

Merck KGaA
Breakthrough Innovation in Cancer Care From Merck Pipeline to Be Presented at ASCO 2020

Darmstadt, Germany (ots/PRNewswire) - - Results from two studies of BAVENCIO® to be featured in ASCO press briefing - Primary efficacy, biomarker and HRQoL analyses for tepotinib?, the first MET inhibitor to have received a regulatory approval for NSCLC with MET gene alterations - Two-year follow-up for first-in-class bifunctional immunotherapy bintrafusp alfa? ...

more
30.04.2020 – 14:00

Merck KGaA
Data From Merck at ASCO 2020 to Showcase Significant Clinical Advances in Cancer Care

Darmstadt, Germany and New York (ots/PRNewswire) - - Not intended for US-, Canada- or UK-based media - ASCO Abstract # BAVENCIO® (avelumab): LBA1, 5061; Bintrafusp alfa (bifunctional fusion protein): 9558; Tepotinib (MET kinase inhibitor): 9556, 9575. - Late-breaking presentation of Phase III JAVELIN Bladder 100 data for BAVENCIO® showing overall survival benefit in ...

more
02.03.2020 – 08:01

Merck KGaA
ERBITUX® Approved for First-line Use in China in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)

Darmstadt, Germany (ots/PRNewswire) - Approval is for ERBITUX® in combination with platinum-based therapy with fluorouracil for the first-line treatment of R/M SCCHN Pivotal Phase III study shows significant improvements with ERBITUX® in combination with platinum-based therapy with fluorouracil in response rate, ...

more
23.09.2019 – 08:01

Merck KGaA
New Data at ESMO 2019 for Merck Highlight Focused Clinical Development and Commitment to Patient Care

Darmstadt, Germany (ots/PRNewswire) - Not intended for distribution in the USA, Canada or the UK Key ESMO Abstracts # BAVENCIO® (avelumab): 1451; 3152; 4174; 4256; 4823; 5113, ERBITUX® (cetuximab): 1212, 2589, 4455, Tepotinib (MET kinase inhibitor): 3930; 5373; 5455, M6620 (ATR inhibitor): 1547, Combinations: ...

more
03.01.2019 – 10:01

ProBioGen AG
ProBioGen's GlymaxX® ADCC Enhancement Technology Used by Betta Pharmaceuticals

Berlin (ots/PRNewswire) - Bispecific Antibody for Cancer Treatment Optimized by GlymaxX® Technology ProBioGen AG, a premier service & technology provider for complex therapeutic antibodies and glycoproteins, announced today that the company achieved an undisclosed milestone payment from Merus N.V. (Nasdaq: MRUS) based on Merus' grant of an exclusive license to ...

more
09.10.2018 – 08:01

Merck KGaA
Merck Data at ESMO 2018 Congress Highlight Multiple Therapeutics with Potential to Transform Cancer Care

Darmstadt, Germany (ots/PRNewswire) - Not intended for distribution in the USA, Canada or UK ESMO Abstract # Avelumab: LBA6_PR, 659P, 1290P, 1291P, 1282P, 877P; M7824 (TGF β-trap/anti-PD-L1):1048O, 1463P, 1931P, 757P, 643P, 642P, 661P; tepotinib (MET kinase inhibitor): 1377O, 621PD, 698P; M6620: 1437P; M3814: ...

more

1